Prioritize the variants that have an impact on gene expression. RNAvision, our analysis platform, prioritizes variants by leveraging complementary information from RNA-seq and clinical data.

Our product is based on statistical methods and software developed by the founding team: OUTRIDER, FRASER, and DROP. These tools enable the direct measurement of a variant's impact at the RNA level, turning variants of uncertain significance into actionable findings and uncovering previously overlooked variants. This approach can improve diagnostic yield by up to 15%, helping to bring an end to the diagnostic odyssey faced by rare disease patients.